Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024 or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to _________

001-32522

Commission file number

China Foods Holdings Ltd.

(Exact name of registrant as specified in its charter)

Delaware		84-1735478
State or other jurisdiction of incorporation or organization		(I.R.S. Employer Identification No.)

Room 2301A, China Resources Building,

26 Harbour Road,

Wanchai, Hong Kong

0000

(Address of principal executive offices)

(Zip Code)

(852) 3618-8608

Registrant’s telephone number, including area code

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically on its corporate Web site, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. The Registrant’s shares were last sold at a price of $0.77 per share. Although the Registrant’s stock has very few trades and limited volume, based on the last sales price of $0.77 shares held by non-affiliates would have a market value of $482,257.93.

As of August 14, 2024, the Registrant had 20,252,309 shares of common stock issued and outstanding.

No documents are incorporated into the text by reference.

Table of Contents

		Page
		No.

	PART I – FINANCIAL INFORMATION

Item 1.	Unaudited Condensed Consolidated Financial Statements	3

	Notes to Unaudited Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	25

Item 4.	Controls and Procedures	25

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	26

Item 1A.	Risk Factors	26

Item 2.	Unregistered Sales of Equity Securities and Proceeds	26

Item 3.	Defaults Upon Senior Securities	26

Item 4.	Mine Safety Disclosure	26

Item 5.	Other Information	26

Item 6.	Exhibits	26

SIGNATURES		27

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

China Foods Holdings Ltd.

Unaudited Condensed Consolidated Balance Sheets

(Currency expressed in United States Dollars (“US$”), except for number of shares)

	June 30, 2024			December 31, 2023
		(Unaudited)			(Audited)
ASSETS
Current Assets
Cash and cash equivalents	$	75,487		$	174,877
Accounts receivable, net		-			38,831
Prepayments, deposits and other receivables		60,653			66,817
Right-of-use assets, net		49,998			20,796
Inventories, net		59,436			48,282
Total Current Assets		245,574			349,603

Non-Current Assets
Plant and equipment, net		16,584			12,981
Intangible assets, net		2,296			2,597
Total Non-Current Assets		18,880			15,578

TOTAL ASSETS	$	264,454		$	365,181

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accrued liabilities and other payables	$	97,248		$	93,395
Customer deposits		104,101			68,885
Lease liabilities		50,116			21,038
Amount due to a director		222,752			232,344
Amount due to a related company		352,900			320,315
Amount due to a related party		352,900			320,315
Income tax payable		1,014			20,019
Total Current Liabilities		828,131			755,996

Stockholders’ (Deficit) Equity
Common stock $0.0001 par value, 100,000,000 shares authorized, 20,252,309 and 20,252,309 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		2,025			2,025
Additional paid-in capital		1,290,355			1,290,355
Accumulated other comprehensive loss		(10,125	)		(7,222	)
Accumulated deficit		(1,845,932	)		(1,675,973	)
Total Stockholders’ Deficit		(563,677	)		(390,815	)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	264,454		$	365,181

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

China Foods Holdings Ltd.

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(Currency expressed in United States Dollars (“US$”), except for number of shares)

(Unaudited)

	2024			2023			2024			2023
	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023

Revenue, net		3,751			6,840			27,617			19,045

Cost of revenue		(1,466	)		(1,538	)		(7,441	)		(11,035	)

Gross profit		2,285			5,302			20,176			8,010

Operating expenses:
Selling and distribution expenses		51			930			4,999			3,258
General and administrative expenses		111,027			138,325			201,471			246,917
Total operating expenses		111,078			139,255			206,470			250,175

Loss from operation		(108,793	)		(133,953	)		(186,294	)		(242,165	)

Other Income:
Interest income		258			241			287			246
Sundry income		137			-			340			336
Total other income		395			241			627			582

Loss before income tax		(108,398	)		(133,712	)		(185,667	)		(241,583	)

Income tax benefit (expense)		100			-			15,708			-

NET LOSS		(108,298	)		(133,712	)		(169,959	)		(241,583	)

Other comprehensive loss:
Foreign currency adjustment loss		(242	)		(3,853	)		(2,903	)		(4,080	)

Comprehensive loss		(108,540	)		(137,565	)		(172,862	)		(245,663	)

Net loss per common share
Basic and diluted	$	(0.01	)	$	(0.01	)	$	(0.01	)	$	(0.01	)

Weighted average number of common share
Basic and diluted		20,252,309			20,252,309			20,252,309			20,252,309

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

China Foods Holdings Ltd.

Unaudited Condensed Consolidated Statements of Changes in Shareholders’ (Deficit) Equity

(Currency expressed in United States Dollars (“US$”), except for number of shares)

	Share		Amount		capital		deficit			loss			deficit
	For the three and six months ended June 30, 2024
	Common Stock				Additional paid-in		Accumulated			Accumulated other comprehensive			Total stockholders’
	Share		Amount		capital		deficit			loss			deficit
				$		$		$			$			$

Balance at January 1, 2024		20,252,309		2,025		1,290,355		(1,675,973	)		(7,222	)		(390,815	)

Net loss for the period		-		-		-		(61,661	)		-			(61,661	)

Foreign currency translation adjustment		-		-		-		-			(2,661	)		(2,661	)

Balance at March 31, 2024		20,252,309		2,025		1,290,355		(1,737,634	)		(9,883	)		(455,137	)

Net loss for the period		-		-		-		(108,298	)		-			(108,298	)

Foreign currency translation adjustment		-		-		-		-			(242	)		(242	)

Balance at June 30, 2024		20,252,309		2,025		1,290,355		(1,845,932	)		(10,125	)		(563,677	)

	For the three and six months ended June 30, 2023
	Common Stock				Additional paid-in		Accumulated			Accumulated other comprehensive			Total stockholders’
	Share		Amount		capital		deficit			loss			deficit
				$		$		$			$			$

Balance at January 1, 2023		20,252,309		2,025		1,290,355		(1,272,273	)		(2,678	)		17,429

Net loss for the period		-		-		-		(107,871	)		-			(107,871	)

Foreign currency translation adjustment		-		-		-		-			(227	)		(227	)

Balance at March 31, 2023		20,252,309		2,025		1,290,355		(1,380,144	)		(2,905	)		(90,669	)
Balance		20,252,309		2,025		1,290,355		(1,380,144	)		(2,905	)		(90,669	)

Net loss for the period		-		-		-		(133,712	)		-			(133,712	)

Foreign currency translation adjustment		-		-		-		-			(3,853	)		(3,853	)

Balance at June 30, 2023		20,252,309		2,025		1,290,355		(1,513,856	)		(6,758	)		(228,234	)
Balance		20,252,309		2,025		1,290,355		(1,513,856	)		(6,758	)		(228,234	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

China Foods Holdings Ltd.

Unaudited Condensed Consolidated Statements of Cash Flows

(Currency expressed in United States Dollars (“US$”))

	2024			2023
	Six months ended June 30,
	2024			2023
Cash flows from operating activities:
Net loss	$	(169,959	)	$	(241,583	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation of plant and equipment		194			28,511
Amortization of intangible assets		233			243
Non-cash lease expense		25,307			20,274
		(144,225	)		(192,555	)
Change in operating assets and liabilities:
Accounts receivables		38,831			16
Prepayments, deposits and other receivables		6,164			13,858
Inventories		(11,154	)		17,080
Accounts payable		-			(6,615	)
Accrued liabilities and other payables		3,853			38,527
Customer deposits		35,216			(3,628	)
Lease liabilities		(25,430	)		(21,168	)
Income tax payable		(19,005	)		(47	)
Net cash used in operating activities		(115,750	)		(154,532	)

Cash flows from investing activities:
Purchase of plant and equipment		(4,169	)		-
Net cash used in investing activities		(4,169	)		-

Cash flows from financing activities:
Advance from related parties		22,993			19,151
Net cash provided by financing activities		22,993			19,151

Foreign currency translation adjustment		(2,464	)		(2,589	)

Net change in cash and cash equivalents		(99,390	)		(137,970	)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		174,877			381,709

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	75,487		$	243,739

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

China Foods Holdings Ltd.

Notes to Unaudited Condensed Consolidated Financial Statements

(Currency expressed in United States Dollars (“US$”), except for number of shares)

NOTE 1 – NATURE OF OPERATIONS

China Foods Holdings Ltd. (the “Company” or “CFOO”) was incorporated in Delaware on January 10, 2019.

The Company is a health and wellness company that develops, markets, promotes and distributes a variety of customized health and wellness care products and services, including supplements, healthy snacks, meal replacements, skincare products, and nutritional consultation services to consumers in China. The Company works with certain licensed healthcare food factories to develop and manufacture products and services that are distributed conventionally through sales agents and also through a network of e-commerce and social media platforms.

Due to the impact of the COVID-19 pandemic in the healthcare industry, the Company also offered a new line of high-end wine products in our online and offline sales platform, to diversify the market demand and customer needs.

The following table depicts the description of the Company’s subsidiaries:

SCHEDULE OF SUBSIDIARIES INFORMATION

Name	Place of incorporation and kind of legal entity	Principal activities	Particulars of registered/ paid up share capital	Effective interest held

Elite Creation Group Limited	BVI, a limited liability company	Investment holding	50,000 issued shares of US$1each		100	%

Alpha Wellness (HK) Limited	Hong Kong, a limited liability company	Investment holding	300,000 issued shares for HK$300,000		100	%

Guangzhou Xiao Xiang Health Industry Company Limited	The PRC, a limited liability company	Sales of healthcare products	RMB 9,000,000		100	%

The Company and its subsidiaries are hereinafter referred to as (the “Company”).

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and consolidation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting, and in accordance with instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements contained in this report reflect all adjustments that are normal and recurring in nature and considered necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The year-end balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. The results of operations for the interim period are not necessarily indicative of the results expected for the full year. These unaudited condensed consolidated financial statements, footnote disclosures and other information should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed on April 16, 2024.

The unaudited condensed consolidated financial statements are presented in US Dollars and include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Significant areas for which management uses estimates include:

●	revenue recognition at point in time and over time;
●	sales returns at point in time and allowances;
●	inventory;
●	estimated lives for tangible and intangible assets; and
●	income tax valuation allowances

These estimates require the use of judgment as future events and the effect of these events cannot be predicted with certainty. The estimates will change as new events occur, as more experience is acquired and as more information is obtained. We evaluate and update our assumptions and estimates on an ongoing basis and we may consult outside experts to assist as considered necessary.

Cash and cash equivalents

Cash and cash equivalents are carried at cost and represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

Accounts receivable

Accounts receivable are recorded at the invoiced amount and do not bear interest, which are due within contractual payment terms, generally 30 to 90 days from completion of service. Credit is extended based on evaluation of a customer’s financial condition, the customer credit-worthiness and their payment history. Accounts receivable outstanding longer than the contractual payment terms are considered past due. Past due balances over 90 days and over a specified amount are reviewed individually for collectability. At the end of fiscal year, the Company specifically evaluates individual customer’s financial condition, credit history, and the current economic conditions to monitor the progress of the collection of accounts receivables. The Company will consider the allowance for doubtful accounts for any estimated losses resulting from the inability of its customers to make required payments. For the receivables that are past due or not being paid according to payment terms, the appropriate actions are taken to exhaust all means of collection, including seeking legal resolution in a court of law. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers. As of June 30, 2024 and December 31, 2023, there was no allowance for doubtful accounts.

Allowance for Expected Credit Losses

In accordance with ASC Topic 326, “Credit Losses – Measurement of Credit Losses on Financial Instruments” (ASC 326), the Company utilizes the current expected credit losses (“CECL”) model to determine an allowance that reflects its best estimate of the expected credit losses on accounts receivable, prepayments, deposits and other receivables which is recorded as a liability to offset the receivables. The CECL model is prepared after considering historical experience, current conditions, and reasonable and supportable economic forecasts to estimate expected credit losses. Accounts receivable, prepayments, deposits and other receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded as a reduction of bad debt expense.

As of June 30, 2024 and December 31, 2023, there was no allowance for expected credit losses.

Inventories

Inventories are stated at the lower of cost or market value (net realizable value), cost being determined on a first-in-first-out method. Costs include material and manufacturing overhead costs. The Company provides inventory allowances based on excess and obsolete inventories determined principally by customer demand. As of June 30, 2024 and December 31, 2023, the Company did not record an allowance for obsolete inventories, nor have there been any write-offs.

Plant and equipment

Plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis over the following expected useful lives from the date on which they become fully operational and after taking into account their estimated residual values:

SCHEDULE OF ESTIMATED USEFUL LIVES

	Expected useful lives	Residual value
Furniture, fixture and equipment	3 years		5	%
Motor vehicle	3.33 to 4 years		5	%
Leasehold improvement	2 years		5	%

Expenditures for repairs and maintenance are expensed as incurred. When assets have been retired or sold, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in the results of operations.

Depreciation expense for the three and six months ended June 30, 2024 were $138 and $194, respectively, and for the three and six months ended June 30, 2023 were $14,160 and $28,511, respectively.

Intangible assets

Intangible assets represented trademarks of their products and are stated at cost less accumulated amortization and any recognized impairment loss. Amortization is provided over the term of their registrations on a straight-line basis, which is 10 years and will expire in 2028.

Amortization expense for the three and six months ended June 30, 2024 were $116 and $233, respectively, and for the three and six months ended June 30, 2023 were $120 and $243, respectively.

Impairment of long-lived assets

In accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as plant and equipment, as well as intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets. There has been no impairment charge for the periods presented.

Revenue recognition

The Company adopted ASC 606 – “Revenue from Contracts with Customers” (“ASC Topic 606”). Under ASC Topic 606, a performance obligation is a promise within a contract to transfer a distinct good or service, or a series of distinct goods and services, to a customer. Revenue is recognized when performance obligations are satisfied and the customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for goods or services. Under the standard, a contract’s transaction price is allocated to each distinct performance obligation. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps:

	●	identify the contract with a customer;
	●	identify the performance obligations in the contract;
	●	determine the transaction price;
	●	allocate the transaction price to performance obligations in the contract; and
	●	recognize revenue as the performance obligation is satisfied.

Currently, the Company operates two business segments.

Healthcare Business mainly provides health consulting advisory services and healthcare and wellness products to the customers.

Revenue is earned from the rendering of health consulting advisory services to the customers. The Company recognizes services revenue over the period in which such services are performed. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

The sale and distribution of the healthcare products, such as (i) Nutrition Catering (ii) Special Health Food (iii) Health Supplement and (iv) Skincare, is the only performance obligation under the fixed-fee arrangements. Revenue is recognized from the sale of their healthcare products upon delivery to the customers, whereas the title and risk of loss are fully transferred to the customers. The Company records its revenues, net of value added taxes (“VAT”) on the majority of the products at the rate of 17% on the invoiced value of sales. The cost, such as shipping cost and material cost, is recognized when the product delivered to the customers. The Company records its cost including taxes.

Wine Business mainly provides wine products to the customers, with a right to return. The Company acts as the principal in substantially all of its customer arrangements and as such, generally records revenues on a gross basis. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Revenue is recognized from the sale of wine products upon delivery to the customers, whereas the title and risk of loss are fully transferred to the customers. The Company records its revenues, net of value added taxes (“VAT”) on the majority of the products at the rate of 17% on the invoiced value of sales. The revenues are presented net of sales returns and discounts. The Company recorded no product sales returns for the six months ended June 30, 2024 and 2023. The cost, such as shipping cost and material cost, is recognized when the product delivered to the customers. The Company records its cost including taxes.

Disaggregation of Revenue

The following table provides information about disaggregated revenue from customers into the nature of the products and services, and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments.

	2024		2023		2024		2023
	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023

Sales of healthcare products	$	3,128	$	665	$	3,128	$	770
Sales of wine products		623		6,175		24,489		18,275

TOTAL	$	3,751	$	6,840	$	27,617	$	19,045

Income taxes

The Company adopted the ASC Topic 740, “Income Taxes” (“ASC Topic 740”) provisions of paragraph 740-10-25-13, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the condensed consolidated financial statements. Under paragraph 740-10-25-13, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Paragraph 740-10-25-13 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no material adjustments to its liabilities for unrecognized income tax benefits according to the provisions of paragraph 740-10-25-13.

The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary.

Foreign currencies translation

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the unaudited condensed consolidated statement of operations.

The reporting currency of the Company is United States Dollar (“US$”) and the accompanying unaudited condensed consolidated financial statements have been expressed in US$. In addition, the Company is operating in Hong Kong SAR and the PRC and maintain its books and record in its local currency, Hong Kong Dollars (“HK$”) and Renminbi (“RMB”), which is a functional currency as being the primary currency of the economic environment in which their operations are conducted. In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the year. The gains and losses resulting from translation of financial statements of foreign subsidiaries are recorded as a separate component of accumulated other comprehensive income within the statements of changes in shareholders’ equity.

Translation of amounts from HK$ and RMB into US$ has been made at the following exchange rates for the six months ended June 30, 2024 and 2023:

	2024		2023
Period-end HK$:US$ exchange rate		0.12808		0.12761
Period average HK$:US$ exchange rate		0.12790		0.12757
Period-end RMB:US$ exchange rate		0.13764		0.13782
Period average RMB:US$ exchange rate		0.13895		0.14436

Net loss per share

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share”. Basic (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common shares outstanding during the period. Diluted (loss) income per share is computed similar to basic (loss) income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Potential common stocks that have an anti-dilutive effect (i.e. those that increase income per share or decrease loss per share) are excluded from the calculation of diluted earnings per share.

Comprehensive income

ASC Topic 220, “Comprehensive Income”, establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying condensed consolidated statements of changes in stockholders’ equity, consists of changes in unrealized gains and losses on foreign currency translation. This comprehensive income is not included in the computation of income tax expense or benefit.

Leases

The Company adopts the FASB Accounting Standards Update (“ASU”) 2016-02 “Leases (Topic 842).” for all periods presented. This standard requires lessees to recognize lease assets (“right of use”) and related lease obligations (“lease liabilities”) on the balance sheet for leases with terms in excess of 12 months.

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities in the consolidated balance sheets. Finance leases are included in finance lease ROU assets and finance lease liabilities in the consolidated balance sheets.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease and finance lease ROU assets and liabilities are recognized, based on the present value of lease payments over the lease term discounted using the rate implicit in the lease. In cases where the implicit rate is not readily determinable, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Related parties

The Company follows the ASC Topic 850-10, “Related Party” for the identification of related parties and disclosure of related party transactions.

Pursuant to section 850-10-20 the related parties include a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and Income-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amount due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

Commitments and contingencies

The Company follows the ASC Topic 450-20, “Commitments” to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

Fair value Measurement

The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC Topic 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC Topic 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

	Level 1	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
	Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
	Level 3	Pricing inputs that are generally observable inputs and not corroborated by market data.

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, accounts receivable, deposits and other receivables, accounts payable, accrued liabilities and other payables, and customer deposits approximate their fair values because of the short maturity of these instruments.

Segment Reporting

ASC Topic 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about geographical areas, business segments and major customers in the unaudited condensed consolidated financial statements. Currently, the Company operates in one reportable operating segment in Hong Kong and China.

Recent accounting pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) amended guidance in ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The revised guidance requires that a public entity disclose significant segment expenses regularly reviewed by the chief operating decision maker (CODM), including public entities with a single reportable segment. The amended guidance is effective for fiscal years beginning in January 2024 and interim periods beginning January 2025 on a retrospective basis. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-07 will have on its condensed consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting periods beginning in January 2025. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its condensed consolidated financial statements.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

NOTE 3 – LIQUIDITY AND GOING CONCERN

The accompanying unaudited condensed consolidated financial statements have been prepared using going concern basis of accounting, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

For the six months ended June 30, 2024, the Company incurred a net loss of $169,959 and suffered from a working capital deficit of $582,557 as of June 30, 2024. The continuation of the Company as a going concern is dependent upon the continued financial support from its stockholders. Management believes the existing stockholders will provide the additional cash to meet with the Company’s obligations as they become due. However, there is no assurance that the Company will be successful in securing sufficient funds to sustain the operations.

These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

NOTE 4 – SEGMENT REPORTING

Currently, the Company has two reportable business segments:

(i)	Healthcare Segment, mainly provides health consulting advisory services and healthcare and wellness products to the customers; and
(ii)	Wine Segment, mainly provides the wine products to the customers.

In the following table, revenue is disaggregated by primary major product line, including a reconciliation of the disaggregated revenue with the reportable segments.

SUMMARY OF REPORTABLE SEGMENTS

	Healthcare Segment			Wine Segment			Total
	Three months ended June 30, 2024
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products	$	3,128		$	-		$	3,128
Sale of wine products		-			623			623
Total revenue		3,128			623			3,751

Cost of revenue:
Sale of healthcare products		(1,141	)		-			(1,141	)
Sale of wine products		-			(325	)		(325	)
Total cost of revenue		(1,141	)		(325	)		(1,466	)

Gross profit		1,987			298			2,285

Operating expenses:
Selling and distribution		-			(51	)		(51	)
General and administrative		(22,819	)		(88,208	)		(111,027	)
Total operating expenses		(22,819	)		(88,259	)		(111,078	)

Segment loss	$	(20,832	)	$	(87,961	)	$	(108,793	)

	Healthcare Segment			Wine Segment			Total
	Three months ended 30 June, 2023
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products	$	665		$	-		$	665
Sale of wine products		-			6,175			6,175
Total revenue		665			6,175			6,840

Cost of revenue:
Sale of healthcare products		(297	)		-			(297	)
Sale of wine products		-			(1,241	)		(1,241	)
Total cost of revenue		(297	)		(1,241	)		(1,538	)

Gross profit		368			4,934			5,302

Operating expenses:
Selling and distribution		-			(930	)		(930	)
General and administrative		(92,536	)		(45,789	)		(138,325	)
Total operating expenses		(92,536	)		(46,719	)		(139,255	)

Segment loss	$	(92,168	)	$	(41,785	)	$	(133,953	)

	Healthcare Segment			Wine Segment			Total
	Six months ended June 30, 2024
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products	$	3,128		$	-		$	3,128
Sale of wine products		-			24,489			24,489
Total revenue		3,128			24,489			27,617

Cost of revenue:
Sale of healthcare products		(1,141	)		-			(1,141	)
Sale of wine products		-			(6,300	)		(6,300	)
Total cost of revenue		(1,141	)		(6,300	)		(7,441	)

Gross profit		1,987			18,189			20,176

Operating Expenses
Selling and distribution		-			(4,999	)		(4,999	)
General and administrative		(22,819	)		(178,652	)		(201,471	)
Total operating expenses		(22,819	)		(183,651	)		(206,470	)

Segment loss	$	(20,832	)	$	(165,462	)	$	(186,294	)

	Healthcare Segment			Wine Segment			Total
	Six months ended June 30, 2023
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products		770			-			770
Sale of wine products		-			18,275			18,275
Total revenue		770			18,275			19,045

Cost of revenue:
Sale of healthcare products		(352	)		-			(352	)
Sale of wine products		-			(10,683	)		(10,683	)
Total cost of revenue		(352	)		(10,683	)		(11,035	)

Gross profit		418			7,592			8,010

Operating Expenses
Selling and distribution		-			(3,258	)		(3,258	)
General and administrative		(155,195	)		(91,722	)		(246,917	)
Total operating expenses		(155,195	)		(94,980	)		(250,175	)

Segment loss	$	(154,777	)	$	(87,388	)	$	(242,165	)

The revenues are based on the countries in which the customer is located. For the three and six months ended June 30, 2024 and 2023, all revenues reported are derived from customers located in China.

NOTE 5 – INVENTORIES

Inventories consisted of the following:

SCHEDULE OF INVENTORIES

	June 30, 2024		December 31, 2023
				(Audited)
Finished goods – Wine products	$	58,058	$	48,282
Finished goods – Healthcare products		1,378		-
Finished goods	$	59,436	$	48,282

For the three and six months ended June 30, 2024 and 2023, no allowance for obsolete inventories was recorded by the Company.

NOTE 6 – CUSTOMER DEPOSITS

Customer deposits represented cash paid to the Company from the customers, for which the Company has an obligation to deliver the orders to satisfy with the customers, or to return the funds, within twelve months.

As of June 30, 2024 and December 31, 2023, the deposit received from customers was $104,101 and $68,885, respectively.

NOTE 7 – AMOUNTS DUE TO A DIRECTOR AND A RELATED COMPANY

The amounts represented temporary advances to the Company by its director and its related company which were unsecured, interest-free and had no fixed terms of repayments.

NOTE 8 – LEASE

The Company leased office and warehouse facilities under various non-cancelable operating leases expiring at the term of 1 year, through May 16, 2025. Upon expiry, the Company renewed and leased an office premise under operating lease with a term of 1 year.

Right of use assets and lease liability – right of use are as follows:

	June 30, 2024		December 31, 2023
				(Audited)
Right-of-use assets	$	49,998	$	20,796

The lease liability – right of use is as follows:

	June 30, 2024		December 31, 2023
				(Audited)
Current portion	$	50,116	$	21,038
Non-current portion		-		-

Total	$	50,116	$	21,038

NOTE 9 – STOCKHOLDERS’ EQUITY

Common Stock

The Company is authorized, subject to limitations prescribed by Delaware law, to issue up to 100,000,000 shares of common stock with a par value of $0.0001.

Dividend Rights

Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine.

Voting Rights

Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Under our Certificate of Incorporation, stockholders do not have the right to cumulate votes for the election of directors.

No Preemptive or Similar Rights

Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions.

Right to Receive Liquidation Distributions

Upon our dissolution, liquidation or winding-up, the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock.

As of June 30, 2024 and December 31, 2023, a total of 20,252,309 and 20,252,309 outstanding shares of common stock were issued, respectively.

Preferred Stock

The Company is not currently authorized to issue shares of preferred stock. The Certificate of Incorporation however, allows the board of directors to authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock in the event that shares of preferred stock are authorized in the future. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the market price of our common stock and the voting and other rights of the holders of common stock. The Company has no current plans to issue any shares of preferred stock.

NOTE 10 – INCOME TAXES

The provision for income taxes consisted of the following:

	2024			2023
	Six months ended June 30,
	2024			2023

Current tax (benefit)	$	(15,708	)	$	-
Deferred tax		-			-
Income tax (benefit) expense	$	(15,708	)	$	-

The Company mainly operates in the PRC that is subject to taxes in the governing jurisdictions in which it operates. The effective tax rate in the years presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rate, as follows:

United States of America

CFOO is registered in the State of Delaware and is subject to US federal corporate income tax. The U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”) was signed into law. The Tax Reform Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. The Company’s policy is to recognize accrued interest and penalties related to unrecognized tax benefits in its income tax provision. The Company has not accrued or paid interest or penalties which were not material to its results of operations for the years presented.

For the six months ended June 30, 2024 and 2023, the income tax benefit was $100 and $0, respectively. As of June 30, 2024 and December 31, 2023, the Company has not accrued any penalties on uncertain tax positions.

As of June 30, 2024, the operation in the United States incurred $153,804 of cumulative net operating losses which can be carried forward indefinitely to offset future taxable income.

BVI

ECGL is incorporated in the British Virgin Islands and is not subject to taxation. In addition, upon payments of dividends by these entities to their shareholder, no British Virgin Islands withholding tax will be imposed.

Hong Kong

The Company’s subsidiary operating in Hong Kong is subject to the Hong Kong Profits Tax at the two-tiered profits tax rates from 8.25% to 16.5% on the estimated assessable profits arising in Hong Kong during the current year, after deducting a tax concession for the tax year. The reconciliation of income tax rate to the effective income tax rate for the six months ended June 30, 2024 and 2023 is as follows:

	2024			2023
	Six months ended June 30,
	2024			2023

Loss before income tax	$	(84,205	)	$	(113,302	)
Statutory income tax rate		8.25	%		8.25	%
Income tax expense at statutory rate		(6,947	)		(9,347	)
Tax adjustments		(15,696	)		1,675
Net operating loss		7,035			7,672
Income tax (benefit) expense	$	(15,608	)	$	-

The PRC

The Company’s subsidiary operating in the PRC is subject to the Corporate Income Tax Law of the PRC at a unified income tax rate of 25%. The reconciliation of income tax rate to the effective income tax rate for the six months ended June 30, 2024 and 2023 is as follows:

	2024			2023
	Six months ended June 30,
	2024			2023

Loss before income taxes	$	(98,712	)	$	(109,557	)
Statutory income tax rate		25	%		25	%
Income tax expense at statutory rate		(24,678	)		(27,389	)
Net operating loss		24,678			27,389
Income tax expense	$	-		$	-

The following table sets forth the significant components of the deferred tax assets of the Company as of June 30, 2024 and December 31, 2023:

SCHEDULE OF DEFERRED TAX ASSETS

	June 30, 2024			December 31, 2023
					(Audited)
Deferred tax assets:
Net operating loss carryforwards
- United States	$	153,804			154,361
- Hong Kong		23,995			16,960
- PRC		377,601			352,923
Net operating loss carry forwards		555,400			524,244
Less: valuation allowance		(555,400	)		(524,244	)
Deferred tax assets, net	$	-		$	-

The Company recognizes interest and penalties, if applicable, related to uncertain tax positions in the income tax provision. There were no reserves for unrecognized tax benefits and no accrued interest related to uncertain tax positions as of June 30, 2024 and December 31, 2023.

The Company files income tax returns in U.S. federal, U.S. state and foreign jurisdictions. With some exceptions, most tax years remain open to examination by the taxing authorities due to the Company’s NOL carryforwards.

NOTE 11 – RELATED PARTY TRANSACTIONS

From time to time, the Company’s director and related company advanced funds to the Company for working capital purpose. Those advances are unsecured, non-interest bearing and due on demand. As of June 30, 2024 and December 31, 2023, the Company owed the balance of $222,752 and $232,344 to its director, and owed the balance of $352,900 and $320,315 to a related company.

Apart from the transactions and balances detailed elsewhere in these accompanying unaudited condensed consolidated financial statements, the Company has no other significant or material related party transactions during the periods presented.

NOTE 12 – CONCENTRATIONS OF RISK

The Company is exposed to the following concentrations of risk:

(a) Major customers

For the three months ended June 30, 2024, a single customer accounted for 64% of the Company’s revenues amounting to $2,407. There is no single customer who accounted for 10% of more of the Company’s revenues for the six months ended June 30, 2024.

For the six months ended June 30, 2023, a single customer accounted for 54% of the Company’s revenues amounting to $10,220. There is no single customer who accounted for 10% of more of the Company’s revenues for the three months ended June 30, 2023.

All the Company’s customers are located in the PRC.

(b) Major vendors

For the three and six months ended June 30, 2024, a single vendor accounted 77% and 15% of the Company’s purchases amounting to $1,128 and $1,128, respectively.

For the three and six months ended June 30, 2023, a single vendor accounted for 100% of the Company’s purchases amounting to $1,398 and $1,398, respectively with accounts payable of $1,398.

All the Company’s vendors are located in the PRC.

Financial instruments that are potentially subject to credit risk consist principally of trade receivables. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

(d) Economic and political risk

The Company’s major operations are conducted in the PRC. Accordingly, the political, economic, and legal environments in the PRC, as well as the general state of the PRC’s economy may influence the Company’s business, financial condition, and results of operations.

(e) Exchange rate risk

The Company cannot guarantee that the current exchange rate will remain steady; therefore there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RMB converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

NOTE 13 - COMMITMENTS AND CONTINGENCIES

As of June 30, 2024, the Company has no material commitments or contingencies.

NOTE 14 - SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before unaudited condensed consolidated financial statements are issued, the Company has evaluated all events or transactions that occurred after June 30, 2024 up through the date the Company issued the unaudited condensed consolidated financial statements. During the period, the Company did not have any material recognizable subsequent events.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This periodic report contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations, business strategies, operating efficiencies or synergies, competitive positions, growth opportunities for existing products, plans and objectives of management. Statements in this periodic report that are not historical facts are hereby identified as forward-looking statements. Our Company and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this Quarterly Report and other filings with the Securities and Exchange Commission and in reports to our Company’s stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company’s control including changes in global economic conditions are forward-looking statements within the meaning of the Act. These statements are made on the basis of management’s views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance, however, that management’s expectations will necessarily come to pass. Factors that may affect forward-looking statements include a wide range of factors that could materially affect future developments and performance, including the following:

Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest; changes in U.S., global or regional economic conditions; changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments; increased competitive pressures, both domestically and internationally; legal and regulatory developments, such as regulatory actions affecting environmental activities; the imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls; adverse weather conditions or natural disasters, such as hurricanes and earthquakes; and labor disputes, which may lead to increased costs or disruption of operations.

This list of factors that may affect future performance and the accuracy of forward-looking statements are illustrative, but by no means exhaustive. Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

Business Overview

We are a health and wellness company that develops, markets, promotes and distributes a variety of customized health and wellness care products and services, including supplements, healthy snacks, meal replacements, skincare products, and nutritional consultation services to consumers in China and Hong Kong. We work with certain licensed healthcare food factories to develop and manufacture products and services that are distributed conventionally through sales agents and also through a network of e-commerce and social media platforms.

In addition to products, we are committed to providing customized science based wellness consultation and service programs to customers. Our diverse products and services target health conscious customers and differentiate based upon age and gender and seek to manage different conditions. We reach out to customers fitting certain health and lifestyle profiles through our offline and online consultation services, and track eating habits and health indicators to provide customized products such as supplements. We believe this will facilitate the ability of customers to monitor, understand and adjust their health practices and lifestyle anytime and anywhere for increased customer engagement and retention.

Due to the impact of the COVID-19 pandemic in the healthcare industry, we have also offered a new line of high-end wine products in our online and offline sales platform, to diversify the market demand and customer needs.

We conduct our business through our wholly owned subsidiary Guangzhou Xiao Xiang Health Industry Company Limited, a limited liability company organized under the laws of China on March 8, 2017 and Alpha Wellness (HK) Limited, a limited liability company organized under the laws of Hong Kong on April 24, 2019. Elite Creation Group, a limited liability company formed under the laws of the British Virgin Islands formed on September 5, 2018, is holding companies without operations.

RESULTS OF OPERATIONS

We have been significantly impacted by COVID-19 global pandemic. In addition to the devastating effects on human life, the pandemic is having a negative ripple effect on the global economy, leading to disruptions and volatility in the global financial markets. China and many other countries have issued policies intended to stop or slow the further spread of the disease.

COVID-19 and China’s response to the pandemic are significantly affecting the economy. Even the COVID-19 pandemic was ended, the ultimate effect of the pandemic is highly uncertain and subject to change. We do not yet know the full extent of the effects on the economy, the markets we serve, our business or our operations.

The following table sets forth certain operational data for the three and six months ended June 30, 2024 and 2023:

	Three Months Ended			Three Months Ended
	June 30, 2024			June 30, 2023
Revenue, net	$	3,751		$	6,840
Cost of revenue		(1,466	)		(1,538	)
Gross profit		2,285			5,302
Total operating expenses		(111,078	)		(139,255	)
Total other income		395			241
Loss before income tax		(108,398	)		(133,712	)
Income tax benefit		100			-
Net loss		(108,298	)		(133,712	)

	Six Months Ended			Six Months Ended
	June 30, 2024			June 30, 2023
Revenue, net	$	27,617		$	19,045
Cost of revenue		(7,441	)		(11,035	)
Gross profit		20,176			8,010
Total operating expenses		(206,470	)		(250,175	)
Total other income		627			582
Loss before income tax		(185,667	)		(241,583	)
Income tax benefit		15,708			-
Net loss		(169,959	)		(241,583	)

Revenue. For the three and six months ended June 30, 2024, we generated revenues of $3,751 and $27,617, respectively. For the comparative three and six months ended June 30, 2023, we generated revenues of $6,840 and $19,045, respectively. There was a significant increase in revenue because of a raising demand in wine market in China.

Cost of Revenue. For the three and six months ended June 30, 2024, the cost of revenue was $1,466 and $7,441, respectively, and as a percentage of net revenue, approximately 39% and 27%, Cost of revenue for the three and six months ended June 30, 2023 was $1,538 and $11,035, respectively, and as a percentage of net revenue, approximately 22% and 58%, respectively. The cost of revenue decreased due to effective sourcing from vendors with lower costs.

Gross Profit. For the three months ended June 30, 2024 and 2023, the gross profit was $2,285 and $5,302, respectively, the gross profit margin was 61% and 78%, respectively. For the six months ended June 30, 2024 and 2023, the gross profit was $20,176 and $8,010, respectively, the gross profit margin was 73% and 42%, respectively. The gross profit increased due to effective sourcing from vendors with lower costs.

Operating Expenses. For the three and six months ended June 30, 2024, the operating cost was $111,078 and $206,470, respectively, and while for the three and six months ended June 30, 2023 was $139,255 and $250,175, respectively. The operating expenses decreased due to a decrease in administrative expenses.

Other Income. For the three and six months ended June 30, 2024, the total other income was $395 and $627, respectively and while for the three and six months ended June 30, 2023 was $241 and $582, respectively. The other income increased due to an increase in receipt of bank interest income.

Net Loss. For the three and six months ended June 30, 2024, we incurred a net loss of $108,298 and $169,959, respectively and for the three and six months ended June 30, 2023, we incurred a net loss of $133,712 and $241,583, respectively. The decrease in net loss was primarily attributable to the increase in revenue from wine market.

Liquidity and Capital Resources

As of June 30, 2024, we had cash and cash equivalents of $75,487.

As of December 31, 2023, we had cash and cash equivalents of $174,877.

We believe that our current cash and other sources of liquidity discussed below are adequate to support general operations for at least the next 12 months.

	Six Months Ended June 30,
	2024			2023
Net cash used in operating activities	$	(115,750	)	$	(154,532	)
Net cash used in investing activities		(4,169	)		-
Net cash provided by financing activities		22,993			19,151

Operating Activities.

For the six months ended June 30, 2024, net cash used in operating activities was $115,750, which primarily consisted of a net loss of $169,959, increase in inventories of $11,154, decrease in lease liabilities of $25,430 and decrease in income tax payable of $19,005. The amounts are partially offset by non-cash adjustments of depreciation of plant and equipment of $194, amortization of intangible asset of $233, non-cash lease expense of $25,307, decrease in accounts receivable of $38,831, decrease in in deposits and other receivables of $6,164, increase in accrued liabilities and other payables of $3,853 and increase in customer deposits of $35,216.

For the six months ended June 30, 2023, net cash used in operating activities was $154,532, which primarily consisted of a net loss of $241,583, decrease in accounts payable of $6,615, decrease in income tax payable of $47, decrease in customer deposits of $3,628 and decrease in lease liabilities of $21,168. The amounts are partially offset by non-cash adjustments of depreciation of plant and equipment of $28,511, amortization of intangible asset of $243, non-cash lease expense of $20,274, decrease in accounts receivable of $16, decrease in deposits and other receivables of $13,858, decrease in inventories of $17,080, and increase in accrued liabilities and other payables of $38,527.

We expect to continue to rely on cash generated through financing from our existing stockholders and private placements of our securities, however, to finance our operations and future acquisitions.

Investing Activities.

For the six months ended June 30, 2024, net cash used in investing activities was $4,169, which primarily consisted of purchase of plant and equipment.

Financing Activities.

For the six months ended June 30, 2024 and 2023, net cash provided by financing activities was $22,993 and $19,151, which primarily consisted of advances from a director and related parties.

Off Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and it is not anticipated that the Company will enter into any off-balance sheet arrangements.

Critical Accounting Policies, Judgments and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto, and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition and results of operations. Critical accounting policies are those that are most important to the presentation of our financial condition and results of operations and require management’s subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management’s current judgments. We believe the following accounting policies are critical in the preparation of our financial statements.

The Company’s accounting policies are more fully described in Note 1 and 2 of the unaudited condensed consolidated financial statements. As discussed in Note 1 and 2, the preparation of the unaudited condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about the future events that affect the amounts reported in the financial statements and the accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual differences could differ from these estimates under different assumptions or conditions. The Company believes that the following addresses the Company’s most critical accounting policies.

Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets will be reflected on the balance sheet when it is determined that it is more likely than not that the asset will be realized. A valuation allowance has currently been recorded to reduce our deferred tax asset to $0.

Forward-looking Statements

The Private Securities Litigation Reform Act of 1995 (the “Act”) provides a safe harbor for forward-looking statements made by or on behalf of our Company. Our Company and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this report and other filings with the Securities and Exchange Commission and in reports to our Company’s stockholders. Management believes that all statements that express expectations and projections with respect to future matters, as well as from developments beyond our Company’s control including changes in global economic conditions are forward-looking statements within the meaning of the Act. These statements are made on the basis of management’s views and assumptions, as of the time the statements are made, regarding future events and business performance. There can be no assurance, however, that management’s expectations will necessarily come to pass. Factors that may affect forward-looking statements include a wide range of factors that could materially affect future developments and performance, including the following:

This list of factors that may affect future performance and the accuracy of forward-looking statements is illustrative, but by no means exhaustive. Accordingly, all forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not required for smaller reporting companies.

Item 4. Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining disclosure controls and procedures for the Company.

(a) Evaluation of Disclosure Controls and Procedures

Our management evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our President and Principal Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected but we believe the controls and procedures do provide a reasonable assurance.

(b) Changes in the Company’s Internal Controls Over Financial Reporting

There have been no changes in internal control over financial reporting that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the internal control over financial reporting.

Part II - Other Information

Item 1. Legal Proceedings

There are no legal proceedings, which are pending or have been threatened against us or any of our officers, directors or control persons of which management is aware.

Item 1A. Risk Factors

Not applicable to smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Proceeds

Recent Sales of Unregistered Securities

We have not sold any restricted securities during the three and six months ended June 30, 2024.

Use of Proceeds of Registered Securities

None; not applicable.

Purchases of Equity Securities by Us and Affiliated Purchasers

During the six months ended June 30, 2024, we have not purchased any equity securities nor have any officers or directors of the Company.

Item 3. Defaults Upon Senior Securities

We are not aware of any defaults upon senior securities. Management has indicated they do not, at this time, intend to pursue the defaults.

Item 4. Mine Safety Disclosure

None; not applicable.

Item 5. Other Information

None; not applicable.

Item 6. Exhibits

	Exhibits No.

	31.1		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
	32.1		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
	101.INS*		Inline XBRL Instance Document
	101.SCH*		Inline XBRL Taxonomy Extension Schema Document
	101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
	101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
	101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
	101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
	104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

These interactive data files are deemed “furnished” and not “filed” or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, or deemed “furnished” and not “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

China Foods Holdings Ltd.

Dated: August 14, 2024	By:	/s/ Kong Xiao Jun
		Kong Xiao Jun
		Chief Executive Officer & Chief Financial Officer

Exhibit 31.1

Rule 13a-14(a) Certification of the Chief Executive Officer

Pursuant to 18 U.S.C. 1350

(Section 302 of the Sarbanes-Oxley Act of 2002)

I, Kong Xiao Jun, certify that:

I have reviewed this report on Form 10-Q of China Foods Holdings Ltd.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2024	By:	/s/ Kong Xiao Jun
		Kong Xiao Jun
		Chief Executive Officer & Chief Financial Officer

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

I, Kong Xiao Jun, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of China Foods Holdings Ltd. on Form 10-Q for the period ended June 30, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of China Foods Holdings Ltd.

Date: August 14, 2024	By:	/s/ Kong Xiao Jun
		Kong Xiao Jun
		Chief Executive Officer & Chief Financial Officer

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2024	Aug. 14, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-32522
Entity Registrant Name	China Foods Holdings Ltd.
Entity Central Index Key	0001310630
Entity Tax Identification Number	84-1735478
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	Room 2301A
Entity Address, Address Line Two	China Resources Building
Entity Address, Address Line Three	26 Harbour Road
Entity Address, City or Town	Wanchai
Entity Address, Country	HK
Entity Address, Postal Zip Code	0000
City Area Code	(852)
Local Phone Number	3618-8608
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,252,309

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 75,487	$ 174,877
Accounts receivable, net		38,831
Prepayments, deposits and other receivables	60,653	66,817
Right-of-use assets, net	49,998	20,796
Inventories, net	59,436	48,282
Total Current Assets	245,574	349,603
Non-Current Assets
Plant and equipment, net	16,584	12,981
Intangible assets, net	2,296	2,597
Total Non-Current Assets	18,880	15,578
TOTAL ASSETS	264,454	365,181
Current Liabilities
Accrued liabilities and other payables	97,248	93,395
Customer deposits	104,101	68,885
Lease liabilities	50,116	21,038
Income tax payable	1,014	20,019
Total Current Liabilities	828,131	755,996
Stockholders’ (Deficit) Equity
Common stock $0.0001 par value, 100,000,000 shares authorized, 20,252,309 and 20,252,309 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	2,025	2,025
Additional paid-in capital	1,290,355	1,290,355
Accumulated other comprehensive loss	(10,125)	(7,222)
Accumulated deficit	(1,845,932)	(1,675,973)
Total Stockholders’ Deficit	(563,677)	(390,815)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	264,454	365,181
Director [Member]
Current Liabilities
Amount due to a related party	222,752	232,344
Related Party [Member]
Current Liabilities
Amount due to a related party	$ 352,900	$ 320,315

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	20,252,309	20,252,309
Common stock, shares outstanding	20,252,309	20,252,309

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue, net	$ 3,751	$ 6,840	$ 27,617	$ 19,045
Cost of revenue	(1,466)	(1,538)	(7,441)	(11,035)
Gross profit	2,285	5,302	20,176	8,010
Operating expenses:
Selling and distribution expenses	51	930	4,999	3,258
General and administrative expenses	111,027	138,325	201,471	246,917
Total operating expenses	111,078	139,255	206,470	250,175
Loss from operation	(108,793)	(133,953)	(186,294)	(242,165)
Other Income:
Interest income	258	241	287	246
Sundry income	137		340	336
Total other income	395	241	627	582
Loss before income tax	(108,398)	(133,712)	(185,667)	(241,583)
Income tax benefit (expense)	100		15,708
NET LOSS	(108,298)	(133,712)	(169,959)	(241,583)
Other comprehensive loss:
Foreign currency adjustment loss	(242)	(3,853)	(2,903)	(4,080)
Comprehensive loss	$ (108,540)	$ (137,565)	$ (172,862)	$ (245,663)
Net loss per common share
Basic	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.01)
Diluted	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.01)
Weighted average number of common share
Basic	20,252,309	20,252,309	20,252,309	20,252,309
Diluted	20,252,309	20,252,309	20,252,309	20,252,309

Condensed Consolidated Statements of Changes in Shareholders' (Deficit) Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2022	$ 2,025	$ 1,290,355	$ (1,272,273)	$ (2,678)	$ 17,429
Balance, shares at Dec. 31, 2022	20,252,309
Net loss for the period			(107,871)		(107,871)
Foreign currency translation adjustment				(227)	(227)
Balance at Mar. 31, 2023	$ 2,025	1,290,355	(1,380,144)	(2,905)	(90,669)
Balance, shares at Mar. 31, 2023	20,252,309
Balance at Dec. 31, 2022	$ 2,025	1,290,355	(1,272,273)	(2,678)	17,429
Balance, shares at Dec. 31, 2022	20,252,309
Net loss for the period					(241,583)
Foreign currency translation adjustment					(4,080)
Balance at Jun. 30, 2023	$ 2,025	1,290,355	(1,513,856)	(6,758)	(228,234)
Balance, shares at Jun. 30, 2023	20,252,309
Balance at Mar. 31, 2023	$ 2,025	1,290,355	(1,380,144)	(2,905)	(90,669)
Balance, shares at Mar. 31, 2023	20,252,309
Net loss for the period			(133,712)		(133,712)
Foreign currency translation adjustment				(3,853)	(3,853)
Balance at Jun. 30, 2023	$ 2,025	1,290,355	(1,513,856)	(6,758)	(228,234)
Balance, shares at Jun. 30, 2023	20,252,309
Balance at Dec. 31, 2023	$ 2,025	1,290,355	(1,675,973)	(7,222)	(390,815)
Balance, shares at Dec. 31, 2023	20,252,309
Net loss for the period			(61,661)		(61,661)
Foreign currency translation adjustment				(2,661)	(2,661)
Balance at Mar. 31, 2024	$ 2,025	1,290,355	(1,737,634)	(9,883)	(455,137)
Balance, shares at Mar. 31, 2024	20,252,309
Balance at Dec. 31, 2023	$ 2,025	1,290,355	(1,675,973)	(7,222)	(390,815)
Balance, shares at Dec. 31, 2023	20,252,309
Net loss for the period					(169,959)
Foreign currency translation adjustment					(2,903)
Balance at Jun. 30, 2024	$ 2,025	1,290,355	(1,845,932)	(10,125)	(563,677)
Balance, shares at Jun. 30, 2024	20,252,309
Balance at Mar. 31, 2024	$ 2,025	1,290,355	(1,737,634)	(9,883)	(455,137)
Balance, shares at Mar. 31, 2024	20,252,309
Net loss for the period			(108,298)		(108,298)
Foreign currency translation adjustment				(242)	(242)
Balance at Jun. 30, 2024	$ 2,025	$ 1,290,355	$ (1,845,932)	$ (10,125)	$ (563,677)
Balance, shares at Jun. 30, 2024	20,252,309

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (169,959)	$ (241,583)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation of plant and equipment	194	28,511
Amortization of intangible assets	233	243
Non-cash lease expense	25,307	20,274
Adjustments to reconcile net loss to net cash used in operating activities, Total	(144,225)	(192,555)
Change in operating assets and liabilities:
Accounts receivables	38,831	16
Prepayments, deposits and other receivables	6,164	13,858
Inventories	(11,154)	17,080
Accounts payable		(6,615)
Accrued liabilities and other payables	3,853	38,527
Customer deposits	35,216	(3,628)
Lease liabilities	(25,430)	(21,168)
Income tax payable	(19,005)	(47)
Net cash used in operating activities	(115,750)	(154,532)
Cash flows from investing activities:
Purchase of plant and equipment	(4,169)
Net cash used in investing activities	(4,169)
Cash flows from financing activities:
Advance from related parties	22,993	19,151
Net cash provided by financing activities	22,993	19,151
Foreign currency translation adjustment	(2,464)	(2,589)
Net change in cash and cash equivalents	(99,390)	(137,970)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	174,877	381,709
CASH AND CASH EQUIVALENTS, END OF PERIOD	75,487	243,739
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest
Cash paid for income taxes

NATURE OF OPERATIONS

6 Months Ended

Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NOTE 1 – NATURE OF OPERATIONS

China Foods Holdings Ltd. (the “Company” or “CFOO”) was incorporated in Delaware on January 10, 2019.

The following table depicts the description of the Company’s subsidiaries:

SCHEDULE OF SUBSIDIARIES INFORMATION

Name	Place of incorporation and kind of legal entity	Principal activities	Particulars of registered/ paid up share capital	Effective interest held

Elite Creation Group Limited	BVI, a limited liability company	Investment holding	50,000 issued shares of US$1each		100	%

Alpha Wellness (HK) Limited	Hong Kong, a limited liability company	Investment holding	300,000 issued shares for HK$300,000		100	%

Guangzhou Xiao Xiang Health Industry Company Limited	The PRC, a limited liability company	Sales of healthcare products	RMB 9,000,000		100	%

The Company and its subsidiaries are hereinafter referred to as (the “Company”).

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and consolidation

Use of estimates

●	revenue recognition at point in time and over time;
●	sales returns at point in time and allowances;
●	inventory;
●	estimated lives for tangible and intangible assets; and
●	income tax valuation allowances

Cash and cash equivalents

Accounts receivable

Allowance for Expected Credit Losses

As of June 30, 2024 and December 31, 2023, there was no allowance for expected credit losses.

Inventories

Plant and equipment

SCHEDULE OF ESTIMATED USEFUL LIVES

	Expected useful lives	Residual value
Furniture, fixture and equipment	3 years		5	%
Motor vehicle	3.33 to 4 years		5	%
Leasehold improvement	2 years		5	%

Depreciation expense for the three and six months ended June 30, 2024 were $138 and $194, respectively, and for the three and six months ended June 30, 2023 were $14,160 and $28,511, respectively.

Intangible assets

Amortization expense for the three and six months ended June 30, 2024 were $116 and $233, respectively, and for the three and six months ended June 30, 2023 were $120 and $243, respectively.

Impairment of long-lived assets

Revenue recognition

	●	identify the contract with a customer;
	●	identify the performance obligations in the contract;
	●	determine the transaction price;
	●	allocate the transaction price to performance obligations in the contract; and
	●	recognize revenue as the performance obligation is satisfied.

Currently, the Company operates two business segments.

Healthcare Business mainly provides health consulting advisory services and healthcare and wellness products to the customers.

Disaggregation of Revenue

	2024		2023		2024		2023
	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023

Sales of healthcare products	$	3,128	$	665	$	3,128	$	770
Sales of wine products		623		6,175		24,489		18,275

TOTAL	$	3,751	$	6,840	$	27,617	$	19,045

Income taxes

Foreign currencies translation

Translation of amounts from HK$ and RMB into US$ has been made at the following exchange rates for the six months ended June 30, 2024 and 2023:

	2024		2023
Period-end HK$:US$ exchange rate		0.12808		0.12761
Period average HK$:US$ exchange rate		0.12790		0.12757
Period-end RMB:US$ exchange rate		0.13764		0.13782
Period average RMB:US$ exchange rate		0.13895		0.14436

Net loss per share

Comprehensive income

Leases

Related parties

The Company follows the ASC Topic 850-10, “Related Party” for the identification of related parties and disclosure of related party transactions.

Commitments and contingencies

Fair value Measurement

	Level 1	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
	Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
	Level 3	Pricing inputs that are generally observable inputs and not corroborated by market data.

Segment Reporting

Recent accounting pronouncements

LIQUIDITY AND GOING CONCERN

6 Months Ended

Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

LIQUIDITY AND GOING CONCERN

NOTE 3 – LIQUIDITY AND GOING CONCERN

SEGMENT REPORTING

6 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE 4 – SEGMENT REPORTING

Currently, the Company has two reportable business segments:

(i)	Healthcare Segment, mainly provides health consulting advisory services and healthcare and wellness products to the customers; and
(ii)	Wine Segment, mainly provides the wine products to the customers.

In the following table, revenue is disaggregated by primary major product line, including a reconciliation of the disaggregated revenue with the reportable segments.

SUMMARY OF REPORTABLE SEGMENTS

	Healthcare Segment			Wine Segment			Total
	Three months ended June 30, 2024
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products	$	3,128		$	-		$	3,128
Sale of wine products		-			623			623
Total revenue		3,128			623			3,751

Cost of revenue:
Sale of healthcare products		(1,141	)		-			(1,141	)
Sale of wine products		-			(325	)		(325	)
Total cost of revenue		(1,141	)		(325	)		(1,466	)

Gross profit		1,987			298			2,285

Operating expenses:
Selling and distribution		-			(51	)		(51	)
General and administrative		(22,819	)		(88,208	)		(111,027	)
Total operating expenses		(22,819	)		(88,259	)		(111,078	)

Segment loss	$	(20,832	)	$	(87,961	)	$	(108,793	)

	Healthcare Segment			Wine Segment			Total
	Three months ended 30 June, 2023
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products	$	665		$	-		$	665
Sale of wine products		-			6,175			6,175
Total revenue		665			6,175			6,840

Cost of revenue:
Sale of healthcare products		(297	)		-			(297	)
Sale of wine products		-			(1,241	)		(1,241	)
Total cost of revenue		(297	)		(1,241	)		(1,538	)

Gross profit		368			4,934			5,302

Operating expenses:
Selling and distribution		-			(930	)		(930	)
General and administrative		(92,536	)		(45,789	)		(138,325	)
Total operating expenses		(92,536	)		(46,719	)		(139,255	)

Segment loss	$	(92,168	)	$	(41,785	)	$	(133,953	)

	Healthcare Segment			Wine Segment			Total
	Six months ended June 30, 2024
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products	$	3,128		$	-		$	3,128
Sale of wine products		-			24,489			24,489
Total revenue		3,128			24,489			27,617

Cost of revenue:
Sale of healthcare products		(1,141	)		-			(1,141	)
Sale of wine products		-			(6,300	)		(6,300	)
Total cost of revenue		(1,141	)		(6,300	)		(7,441	)

Gross profit		1,987			18,189			20,176

Operating Expenses
Selling and distribution		-			(4,999	)		(4,999	)
General and administrative		(22,819	)		(178,652	)		(201,471	)
Total operating expenses		(22,819	)		(183,651	)		(206,470	)

Segment loss	$	(20,832	)	$	(165,462	)	$	(186,294	)

	Healthcare Segment			Wine Segment			Total
	Six months ended June 30, 2023
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products		770			-			770
Sale of wine products		-			18,275			18,275
Total revenue		770			18,275			19,045

Cost of revenue:
Sale of healthcare products		(352	)		-			(352	)
Sale of wine products		-			(10,683	)		(10,683	)
Total cost of revenue		(352	)		(10,683	)		(11,035	)

Gross profit		418			7,592			8,010

Operating Expenses
Selling and distribution		-			(3,258	)		(3,258	)
General and administrative		(155,195	)		(91,722	)		(246,917	)
Total operating expenses		(155,195	)		(94,980	)		(250,175	)

Segment loss	$	(154,777	)	$	(87,388	)	$	(242,165	)

The revenues are based on the countries in which the customer is located. For the three and six months ended June 30, 2024 and 2023, all revenues reported are derived from customers located in China.

INVENTORIES

6 Months Ended

Jun. 30, 2024

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 5 – INVENTORIES

Inventories consisted of the following:

SCHEDULE OF INVENTORIES

	June 30, 2024		December 31, 2023
				(Audited)
Finished goods – Wine products	$	58,058	$	48,282
Finished goods – Healthcare products		1,378		-
Finished goods	$	59,436	$	48,282

For the three and six months ended June 30, 2024 and 2023, no allowance for obsolete inventories was recorded by the Company.

CUSTOMER DEPOSITS

6 Months Ended

Jun. 30, 2024

Customer Deposits

CUSTOMER DEPOSITS

NOTE 6 – CUSTOMER DEPOSITS

As of June 30, 2024 and December 31, 2023, the deposit received from customers was $104,101 and $68,885, respectively.

AMOUNTS DUE TO A DIRECTOR AND A RELATED COMPANY

6 Months Ended

Jun. 30, 2024

Amounts Due To Director And Related Company

AMOUNTS DUE TO A DIRECTOR AND A RELATED COMPANY

NOTE 7 – AMOUNTS DUE TO A DIRECTOR AND A RELATED COMPANY

The amounts represented temporary advances to the Company by its director and its related company which were unsecured, interest-free and had no fixed terms of repayments.

LEASE

6 Months Ended

Jun. 30, 2024

Lease

LEASE

NOTE 8 – LEASE

Right of use assets and lease liability – right of use are as follows:

	June 30, 2024		December 31, 2023
				(Audited)
Right-of-use assets	$	49,998	$	20,796

The lease liability – right of use is as follows:

	June 30, 2024		December 31, 2023
				(Audited)
Current portion	$	50,116	$	21,038
Non-current portion		-		-

Total	$	50,116	$	21,038

STOCKHOLDERS’ EQUITY

6 Months Ended

Jun. 30, 2024

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 9 – STOCKHOLDERS’ EQUITY

Common Stock

The Company is authorized, subject to limitations prescribed by Delaware law, to issue up to 100,000,000 shares of common stock with a par value of $0.0001.

Dividend Rights

Voting Rights

No Preemptive or Similar Rights

Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions.

Right to Receive Liquidation Distributions

As of June 30, 2024 and December 31, 2023, a total of 20,252,309 and 20,252,309 outstanding shares of common stock were issued, respectively.

Preferred Stock

INCOME TAXES

6 Months Ended

Jun. 30, 2024

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 10 – INCOME TAXES

The provision for income taxes consisted of the following:

	2024			2023
	Six months ended June 30,
	2024			2023

Current tax (benefit)	$	(15,708	)	$	-
Deferred tax		-			-
Income tax (benefit) expense	$	(15,708	)	$	-

United States of America

As of June 30, 2024, the operation in the United States incurred $153,804 of cumulative net operating losses which can be carried forward indefinitely to offset future taxable income.

BVI

Hong Kong

	2024			2023
	Six months ended June 30,
	2024			2023

Loss before income tax	$	(84,205	)	$	(113,302	)
Statutory income tax rate		8.25	%		8.25	%
Income tax expense at statutory rate		(6,947	)		(9,347	)
Tax adjustments		(15,696	)		1,675
Net operating loss		7,035			7,672
Income tax (benefit) expense	$	(15,608	)	$	-

The PRC

	2024			2023
	Six months ended June 30,
	2024			2023

Loss before income taxes	$	(98,712	)	$	(109,557	)
Statutory income tax rate		25	%		25	%
Income tax expense at statutory rate		(24,678	)		(27,389	)
Net operating loss		24,678			27,389
Income tax expense	$	-		$	-

The following table sets forth the significant components of the deferred tax assets of the Company as of June 30, 2024 and December 31, 2023:

SCHEDULE OF DEFERRED TAX ASSETS

	June 30, 2024			December 31, 2023
					(Audited)
Deferred tax assets:
Net operating loss carryforwards
- United States	$	153,804			154,361
- Hong Kong		23,995			16,960
- PRC		377,601			352,923
Net operating loss carry forwards		555,400			524,244
Less: valuation allowance		(555,400	)		(524,244	)
Deferred tax assets, net	$	-		$	-

RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2024

RELATED PARTY TRANSACTIONS

NOTE 11 – RELATED PARTY TRANSACTIONS

CONCENTRATIONS OF RISK

6 Months Ended

Jun. 30, 2024

Risks and Uncertainties [Abstract]

CONCENTRATIONS OF RISK

NOTE 12 – CONCENTRATIONS OF RISK

The Company is exposed to the following concentrations of risk:

(a) Major customers

All the Company’s customers are located in the PRC.

(b) Major vendors

For the three and six months ended June 30, 2024, a single vendor accounted 77% and 15% of the Company’s purchases amounting to $1,128 and $1,128, respectively.

For the three and six months ended June 30, 2023, a single vendor accounted for 100% of the Company’s purchases amounting to $1,398 and $1,398, respectively with accounts payable of $1,398.

All the Company’s vendors are located in the PRC.

(d) Economic and political risk

(e) Exchange rate risk

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 13 - COMMITMENTS AND CONTINGENCIES

As of June 30, 2024, the Company has no material commitments or contingencies.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 14 - SUBSEQUENT EVENTS

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Basis of presentation and consolidation

Basis of presentation and consolidation

Use of estimates

Use of estimates

●	revenue recognition at point in time and over time;
●	sales returns at point in time and allowances;
●	inventory;
●	estimated lives for tangible and intangible assets; and
●	income tax valuation allowances

Cash and cash equivalents

Cash and cash equivalents

Accounts receivable

Accounts receivable

Allowance for Expected Credit Losses

Allowance for Expected Credit Losses

As of June 30, 2024 and December 31, 2023, there was no allowance for expected credit losses.

Inventories

Inventories

Plant and equipment

Plant and equipment

SCHEDULE OF ESTIMATED USEFUL LIVES

	Expected useful lives	Residual value
Furniture, fixture and equipment	3 years		5	%
Motor vehicle	3.33 to 4 years		5	%
Leasehold improvement	2 years		5	%

Depreciation expense for the three and six months ended June 30, 2024 were $138 and $194, respectively, and for the three and six months ended June 30, 2023 were $14,160 and $28,511, respectively.

Intangible assets

Intangible assets

Amortization expense for the three and six months ended June 30, 2024 were $116 and $233, respectively, and for the three and six months ended June 30, 2023 were $120 and $243, respectively.

Impairment of long-lived assets

Impairment of long-lived assets

Revenue recognition

Revenue recognition

	●	identify the contract with a customer;
	●	identify the performance obligations in the contract;
	●	determine the transaction price;
	●	allocate the transaction price to performance obligations in the contract; and
	●	recognize revenue as the performance obligation is satisfied.

Currently, the Company operates two business segments.

Healthcare Business mainly provides health consulting advisory services and healthcare and wellness products to the customers.

Disaggregation of Revenue

Disaggregation of Revenue

	2024		2023		2024		2023
	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023

Sales of healthcare products	$	3,128	$	665	$	3,128	$	770
Sales of wine products		623		6,175		24,489		18,275

TOTAL	$	3,751	$	6,840	$	27,617	$	19,045

Income taxes

Income taxes

Foreign currencies translation

Foreign currencies translation

Translation of amounts from HK$ and RMB into US$ has been made at the following exchange rates for the six months ended June 30, 2024 and 2023:

	2024		2023
Period-end HK$:US$ exchange rate		0.12808		0.12761
Period average HK$:US$ exchange rate		0.12790		0.12757
Period-end RMB:US$ exchange rate		0.13764		0.13782
Period average RMB:US$ exchange rate		0.13895		0.14436

Net loss per share

Net loss per share

Comprehensive income

Comprehensive income

Leases

Leases

Related parties

Related parties

The Company follows the ASC Topic 850-10, “Related Party” for the identification of related parties and disclosure of related party transactions.

Commitments and contingencies

Commitments and contingencies

Fair value Measurement

Fair value Measurement

	Level 1	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
	Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
	Level 3	Pricing inputs that are generally observable inputs and not corroborated by market data.

Segment Reporting

Segment Reporting

Recent accounting pronouncements

Recent accounting pronouncements

NATURE OF OPERATIONS (Tables)

6 Months Ended

Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SCHEDULE OF SUBSIDIARIES INFORMATION

The following table depicts the description of the Company’s subsidiaries:

SCHEDULE OF SUBSIDIARIES INFORMATION

Name	Place of incorporation and kind of legal entity	Principal activities	Particulars of registered/ paid up share capital	Effective interest held

Elite Creation Group Limited	BVI, a limited liability company	Investment holding	50,000 issued shares of US$1each		100	%

Alpha Wellness (HK) Limited	Hong Kong, a limited liability company	Investment holding	300,000 issued shares for HK$300,000		100	%

Guangzhou Xiao Xiang Health Industry Company Limited	The PRC, a limited liability company	Sales of healthcare products	RMB 9,000,000		100	%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

SCHEDULE OF ESTIMATED USEFUL LIVES

	Expected useful lives	Residual value
Furniture, fixture and equipment	3 years		5	%
Motor vehicle	3.33 to 4 years		5	%
Leasehold improvement	2 years		5	%

SCHEDULE OF DISAGGREGATED REVENUE WITH REPORTABLE SEGMENTS

	2024		2023		2024		2023
	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023

Sales of healthcare products	$	3,128	$	665	$	3,128	$	770
Sales of wine products		623		6,175		24,489		18,275

TOTAL	$	3,751	$	6,840	$	27,617	$	19,045

SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES

Translation of amounts from HK$ and RMB into US$ has been made at the following exchange rates for the six months ended June 30, 2024 and 2023:

	2024		2023
Period-end HK$:US$ exchange rate		0.12808		0.12761
Period average HK$:US$ exchange rate		0.12790		0.12757
Period-end RMB:US$ exchange rate		0.13764		0.13782
Period average RMB:US$ exchange rate		0.13895		0.14436

SEGMENT REPORTING (Tables)

6 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

SUMMARY OF REPORTABLE SEGMENTS

	Healthcare Segment			Wine Segment			Total
	Three months ended June 30, 2024
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products	$	3,128		$	-		$	3,128
Sale of wine products		-			623			623
Total revenue		3,128			623			3,751

Cost of revenue:
Sale of healthcare products		(1,141	)		-			(1,141	)
Sale of wine products		-			(325	)		(325	)
Total cost of revenue		(1,141	)		(325	)		(1,466	)

Gross profit		1,987			298			2,285

Operating expenses:
Selling and distribution		-			(51	)		(51	)
General and administrative		(22,819	)		(88,208	)		(111,027	)
Total operating expenses		(22,819	)		(88,259	)		(111,078	)

Segment loss	$	(20,832	)	$	(87,961	)	$	(108,793	)

	Healthcare Segment			Wine Segment			Total
	Three months ended 30 June, 2023
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products	$	665		$	-		$	665
Sale of wine products		-			6,175			6,175
Total revenue		665			6,175			6,840

Cost of revenue:
Sale of healthcare products		(297	)		-			(297	)
Sale of wine products		-			(1,241	)		(1,241	)
Total cost of revenue		(297	)		(1,241	)		(1,538	)

Gross profit		368			4,934			5,302

Operating expenses:
Selling and distribution		-			(930	)		(930	)
General and administrative		(92,536	)		(45,789	)		(138,325	)
Total operating expenses		(92,536	)		(46,719	)		(139,255	)

Segment loss	$	(92,168	)	$	(41,785	)	$	(133,953	)

	Healthcare Segment			Wine Segment			Total
	Six months ended June 30, 2024
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products	$	3,128		$	-		$	3,128
Sale of wine products		-			24,489			24,489
Total revenue		3,128			24,489			27,617

Cost of revenue:
Sale of healthcare products		(1,141	)		-			(1,141	)
Sale of wine products		-			(6,300	)		(6,300	)
Total cost of revenue		(1,141	)		(6,300	)		(7,441	)

Gross profit		1,987			18,189			20,176

Operating Expenses
Selling and distribution		-			(4,999	)		(4,999	)
General and administrative		(22,819	)		(178,652	)		(201,471	)
Total operating expenses		(22,819	)		(183,651	)		(206,470	)

Segment loss	$	(20,832	)	$	(165,462	)	$	(186,294	)

	Healthcare Segment			Wine Segment			Total
	Six months ended June 30, 2023
	Healthcare Segment			Wine Segment			Total
Revenue from external customers:
Sale of healthcare products		770			-			770
Sale of wine products		-			18,275			18,275
Total revenue		770			18,275			19,045

Cost of revenue:
Sale of healthcare products		(352	)		-			(352	)
Sale of wine products		-			(10,683	)		(10,683	)
Total cost of revenue		(352	)		(10,683	)		(11,035	)

Gross profit		418			7,592			8,010

Operating Expenses
Selling and distribution		-			(3,258	)		(3,258	)
General and administrative		(155,195	)		(91,722	)		(246,917	)
Total operating expenses		(155,195	)		(94,980	)		(250,175	)

Segment loss	$	(154,777	)	$	(87,388	)	$	(242,165	)

INVENTORIES (Tables)

6 Months Ended

Jun. 30, 2024

Inventory Disclosure [Abstract]

SCHEDULE OF INVENTORIES

Inventories consisted of the following:

SCHEDULE OF INVENTORIES

	June 30, 2024		December 31, 2023
				(Audited)
Finished goods – Wine products	$	58,058	$	48,282
Finished goods – Healthcare products		1,378		-
Finished goods	$	59,436	$	48,282

LEASE (Tables)

6 Months Ended

Jun. 30, 2024

Lease

SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY

Right of use assets and lease liability – right of use are as follows:

	June 30, 2024		December 31, 2023
				(Audited)
Right-of-use assets	$	49,998	$	20,796

The lease liability – right of use is as follows:

	June 30, 2024		December 31, 2023
				(Audited)
Current portion	$	50,116	$	21,038
Non-current portion		-		-

Total	$	50,116	$	21,038

INCOME TAXES (Tables)

6 Months Ended

Jun. 30, 2024

Operating Loss Carryforwards [Line Items]

SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE

The provision for income taxes consisted of the following:

	2024			2023
	Six months ended June 30,
	2024			2023

Current tax (benefit)	$	(15,708	)	$	-
Deferred tax		-			-
Income tax (benefit) expense	$	(15,708	)	$	-

SCHEDULE OF DEFERRED TAX ASSETS

The following table sets forth the significant components of the deferred tax assets of the Company as of June 30, 2024 and December 31, 2023:

SCHEDULE OF DEFERRED TAX ASSETS

	June 30, 2024			December 31, 2023
					(Audited)
Deferred tax assets:
Net operating loss carryforwards
- United States	$	153,804			154,361
- Hong Kong		23,995			16,960
- PRC		377,601			352,923
Net operating loss carry forwards		555,400			524,244
Less: valuation allowance		(555,400	)		(524,244	)
Deferred tax assets, net	$	-		$	-

State Administration of Taxation, China [Member]

Operating Loss Carryforwards [Line Items]

SCHEDULE OF RECONCILIATION TAX RATE TO EFFECTIVE INCOME TAX RATE

	2024			2023
	Six months ended June 30,
	2024			2023

Loss before income taxes	$	(98,712	)	$	(109,557	)
Statutory income tax rate		25	%		25	%
Income tax expense at statutory rate		(24,678	)		(27,389	)
Net operating loss		24,678			27,389
Income tax expense	$	-		$	-

Inland Revenue, Hong Kong [Member]

Operating Loss Carryforwards [Line Items]

SCHEDULE OF RECONCILIATION TAX RATE TO EFFECTIVE INCOME TAX RATE

	2024			2023
	Six months ended June 30,
	2024			2023

Loss before income tax	$	(84,205	)	$	(113,302	)
Statutory income tax rate		8.25	%		8.25	%
Income tax expense at statutory rate		(6,947	)		(9,347	)
Tax adjustments		(15,696	)		1,675
Net operating loss		7,035			7,672
Income tax (benefit) expense	$	(15,608	)	$	-

SCHEDULE OF SUBSIDIARIES INFORMATION (Details) - 6 months ended Jun. 30, 2024	USD ($) shares	HKD ($) shares	CNY (¥) shares
Elite Creation Group Limited [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Place of incorporation and kind of legal entity	BVI, a limited liability company	BVI, a limited liability company	BVI, a limited liability company
Principal activities	Investment holding	Investment holding	Investment holding
Stock issued during period, shares, new issues \| shares	50,000	50,000	50,000
Stock issued during period, value, new issues \| $	$ 1
Effective interest held percentage	100.00%	100.00%	100.00%
Alpha Wellness (HK) Limited [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Place of incorporation and kind of legal entity	Hong Kong, a limited liability company	Hong Kong, a limited liability company	Hong Kong, a limited liability company
Principal activities	Investment holding	Investment holding	Investment holding
Stock issued during period, shares, new issues \| shares	300,000	300,000	300,000
Stock issued during period, value, new issues \| $		$ 300,000
Effective interest held percentage	100.00%	100.00%	100.00%
Guangzhou Xiao Xiang Health Industry Company Limited [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Place of incorporation and kind of legal entity	The PRC, a limited liability company	The PRC, a limited liability company	The PRC, a limited liability company
Principal activities	Sales of healthcare products	Sales of healthcare products	Sales of healthcare products
Stock issued during period, value, new issues \| ¥			¥ 9,000,000
Effective interest held percentage	100.00%	100.00%	100.00%

SCHEDULE OF ESTIMATED USEFUL LIVES (Details)	Jun. 30, 2024
Furniture, Fixture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Residual value	5.00%
Motor Vehicles [Member]
Property, Plant and Equipment [Line Items]
Residual value	5.00%
Motor Vehicles [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years 3 months 29 days
Motor Vehicles [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	4 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	2 years
Residual value	5.00%

SCHEDULE OF DISAGGREGATED REVENUE WITH REPORTABLE SEGMENTS (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Product Information [Line Items]
TOTAL	$ 3,751	$ 6,840	$ 27,617	$ 19,045
Sale Of Healthcare Products [Member]
Product Information [Line Items]
TOTAL	3,128	665	3,128	770
Sale of Wine Products [Member]
Product Information [Line Items]
TOTAL	$ 623	$ 6,175	$ 24,489	$ 18,275

SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)	Jun. 30, 2024	Jun. 30, 2023
Period-end HK$:US$ Exchange Rate [Member]
Offsetting Assets [Line Items]
Foreign currency translation exchange rates	0.12808	0.12761
Period-average HK$:US$ Exchange Rate [Member]
Offsetting Assets [Line Items]
Foreign currency translation exchange rates	0.12790	0.12757
Period-end RMB:US$ Exchange Rate [Member]
Offsetting Assets [Line Items]
Foreign currency translation exchange rates	0.13764	0.13782
Period-average RMB:US$ Exchange Rate [Member]
Offsetting Assets [Line Items]
Foreign currency translation exchange rates	0.13895	0.14436

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) Integer Segment	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Allowance for doubtful accounts	$ 0		$ 0		$ 0
Allowance for expected credit losses	0		0		$ 0
Depreciation expense	138	$ 14,160	194	$ 28,511
Amortization of intangible assets	$ 116	$ 120	$ 233	243
Sales tax percentage			17.00%
Product sales returns			$ 0	$ 0
Income tax likelihood, description			greater than fifty percent (50%) likelihood of being realized upon ultimate settlement
Number of reportable segment \| Segment			2
Hong Kong and China [Member]
Number of reportable segment \| Integer			1
Number of operating segment \| Integer			1

LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 108,298	$ 61,661	$ 133,712	$ 107,871	$ 169,959	$ 241,583
Working capital deficit	$ 582,557				$ 582,557

SUMMARY OF REPORTABLE SEGMENTS (Details) - USD ($)	3 Months Ended		6 Months Ended
SUMMARY OF REPORTABLE SEGMENTS (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Segment Reporting Information [Line Items]
Total revenue	$ 3,751	$ 6,840	$ 27,617	$ 19,045
Total cost of revenue	(1,466)	(1,538)	(7,441)	(11,035)
Gross profit	2,285	5,302	20,176	8,010
Selling and distribution	(51)	(930)	(4,999)	(3,258)
General and administrative	(111,027)	(138,325)	(201,471)	(246,917)
Total operating expenses	(111,078)	(139,255)	(206,470)	(250,175)
Loss from operation	(108,793)	(133,953)	(186,294)	(242,165)
Sale of Healthcare Products [Member]
Segment Reporting Information [Line Items]
Total revenue	3,128	665	3,128	770
Total cost of revenue	(1,141)	(297)	(1,141)	(352)
Sale of Wine Products [Member]
Segment Reporting Information [Line Items]
Total revenue	623	6,175	24,489	18,275
Total cost of revenue	(325)	(1,241)	(6,300)	(10,683)
Healthcare Segment [Member]
Segment Reporting Information [Line Items]
Total revenue	3,128	665	3,128	770
Total cost of revenue	(1,141)	(297)	(1,141)	(352)
Gross profit	1,987	368	1,987	418
Selling and distribution
General and administrative	(22,819)	(92,536)	(22,819)	(155,195)
Total operating expenses	(22,819)	(92,536)	(22,819)	(155,195)
Loss from operation	(20,832)	(92,168)	(20,832)	(154,777)
Healthcare Segment [Member] \| Sale of Healthcare Products [Member]
Segment Reporting Information [Line Items]
Total revenue	3,128	665	3,128	770
Total cost of revenue	(1,141)	(297)	(1,141)	(352)
Healthcare Segment [Member] \| Sale of Wine Products [Member]
Segment Reporting Information [Line Items]
Total revenue
Total cost of revenue
Wine Segment [Member]
Segment Reporting Information [Line Items]
Total revenue	623	6,175	24,489	18,275
Total cost of revenue	(325)	(1,241)	(6,300)	(10,683)
Gross profit	298	4,934	18,189	7,592
Selling and distribution	(51)	(930)	(4,999)	(3,258)
General and administrative	(88,208)	(45,789)	(178,652)	(91,722)
Total operating expenses	(88,259)	(46,719)	(183,651)	(94,980)
Loss from operation	(87,961)	(41,785)	(165,462)	(87,388)
Wine Segment [Member] \| Sale of Healthcare Products [Member]
Segment Reporting Information [Line Items]
Total revenue
Total cost of revenue
Wine Segment [Member] \| Sale of Wine Products [Member]
Segment Reporting Information [Line Items]
Total revenue	623	6,175	24,489	18,275
Total cost of revenue	$ (325)	$ (1,241)	$ (6,300)	$ (10,683)

SEGMENT REPORTING (Details Narrative)	6 Months Ended
SEGMENT REPORTING (Details Narrative)	Jun. 30, 2024 Segment
Segment Reporting [Abstract]
Number of reportable segments	2

SCHEDULE OF INVENTORIES (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Finished goods	$ 59,436	$ 48,282
Wine Products [Member]
Finished goods	58,058	48,282
Healthcare Products [Member]
Finished goods	$ 1,378

INVENTORIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
INVENTORIES (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Inventory Disclosure [Abstract]
Allowance for obsolete inventories	$ 0	$ 0	$ 0	$ 0

CUSTOMER DEPOSITS (Details Narrative) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Customer Deposits
Deposit received from customers	$ 104,101	$ 68,885

SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Lease
Right-of-use assets	$ 49,998	$ 20,796
Current portion	50,116	21,038
Non-current portion
Total	$ 50,116	$ 21,038

LEASE (Details Narrative)	6 Months Ended
LEASE (Details Narrative)	Jun. 30, 2024
Property, Plant and Equipment [Line Items]
Operating lease, description	The Company leased office and warehouse facilities under various non-cancelable operating leases expiring at the term of 1 year, through May 16, 2025.
Lease term	1 year
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Lease term	1 year

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Equity [Abstract]
Common stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares, issued	20,252,309	20,252,309
Common stock, shares, outstanding	20,252,309	20,252,309

SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Current tax (benefit)			$ (15,708)
Deferred tax
Income tax (benefit) expense	$ (100)		$ (15,708)

SCHEDULE OF RECONCILIATION TAX RATE TO EFFECTIVE INCOME TAX RATE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating Loss Carryforwards [Line Items]
Loss before income taxes	$ (108,398)	$ (133,712)	$ (185,667)	$ (241,583)
Statutory income tax rate			21.00%
Income tax expense	$ (100)		$ (15,708)
Inland Revenue, Hong Kong [Member]
Operating Loss Carryforwards [Line Items]
Loss before income taxes			$ (84,205)	$ (113,302)
Statutory income tax rate			8.25%	8.25%
Income tax expense at statutory rate			$ (6,947)	$ (9,347)
Tax adjustments			(15,696)	1,675
Net operating loss			7,035	7,672
Income tax expense			(15,608)
State Administration of Taxation, China [Member]
Operating Loss Carryforwards [Line Items]
Loss before income taxes			$ (98,712)	$ (109,557)
Statutory income tax rate			25.00%	25.00%
Income tax expense at statutory rate			$ (24,678)	$ (27,389)
Net operating loss			24,678	27,389
Income tax expense

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Net operating loss carry forwards	$ 555,400	$ 524,244
Less: valuation allowance	(555,400)	(524,244)
Deferred tax assets, net
UNITED STATES
Net operating loss carry forwards	153,804	154,361
HONG KONG
Net operating loss carry forwards	23,995	16,960
CHINA
Net operating loss carry forwards	$ 377,601	$ 352,923

INCOME TAXES (Details Narrative) - USD ($)	6 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Income tax description	The Tax Reform Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. The Company’s policy is to recognize accrued interest and penalties related to unrecognized tax benefits in its income tax provision. The Company has not accrued or paid interest or penalties which were not material to its results of operations for the years presented
Corporate tax rate	21.00%
Penalty on uncertain tax position	$ 100	$ 0
Cumulative net operating losses	153,804
Unrecognized tax benefits	$ 0		$ 0
HONG KONG
Income tax description	The Company’s subsidiary operating in Hong Kong is subject to the Hong Kong Profits Tax at the two-tiered profits tax rates from 8.25% to 16.5% on the estimated assessable profits arising in Hong Kong during the current year, after deducting a tax concession for the tax year
CHINA
Income tax description	The Company’s subsidiary operating in the PRC is subject to the Corporate Income Tax Law of the PRC at a unified income tax rate of 25%

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Director [Member]
Related Party Transaction [Line Items]
Due to related company	$ 222,752	$ 232,344
Related Party [Member]
Related Party Transaction [Line Items]
Due to related company	$ 352,900	$ 320,315

CONCENTRATIONS OF RISK (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
CONCENTRATIONS OF RISK (Details Narrative) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Concentration Risk [Line Items]
Revenue, net	$ 3,751	$ 6,840	$ 27,617	$ 19,045
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| Single Customer [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	64.00%			54.00%
Revenue, net	$ 2,407			$ 10,220
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| Single Vendor [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	77.00%	100.00%	15.00%	100.00%
Purchases		$ 1,398		$ 1,398
Accounts payable		$ 1,398		$ 1,398
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| Vendor [Member]
Concentration Risk [Line Items]
Purchases	$ 1,128		$ 1,128